Oppenheimer Asset Management Takes Stake in Artivion, Inc. (

Institutional investor Oppenheimer Asset Management Inc. revealed in a recent 13F filing that it acquired a new position in Artivion, Inc. (NYSE: AORT) during the second quarter. The firm purchased approximately 21,513 shares, amounting to roughly $669,000, which represented about 0.05% of Artivion’s outstanding stock at the end of the period. This move comes as several other institutional investors either increased or entered new holdings in Artivion over the same period. Notably, MCF Advisors LLC nearly doubled its stake in the first quarter, while EntryPoint Capital LLC, Natixis Advisors LLC and Zürcher Kantonalbank also boosted or initiated their investments. For context, Artivion manufactures and distributes medical devices and implantable human tissues—products such as its BioGlue surgical adhesive, bovine‑pericardial patches, and aortic arch stent grafts. The shift in holdings signals that key money‑managers see growth potential in the company or believe the market undervalues its assets and positioning. #investmentnews #Artivion #institutionalinvesting #healthtechstocks #SlimScan #GrowthStocks #CANSLIM